Profile data is unavailable for this security.
About the company
Bioventus Inc. is a medical device company. The Company’s portfolio of products is grouped into three areas. Its Pain Treatments include the Knee Osteoarthritis (KOA) area, and Peripheral Nerve Stimulation (PNS) area. Its Surgical Solutions include Ultrasonics, which offers precision bone resection for patients with degenerative spine conditions and spinal deformities, and Bone Graft Substitutes (BGS), which includes a range of products that facilitate optimal bone fusion following a surgical procedure. Its Restorative Therapies comprise Fracture Care that provide low-intensity pulse ultrasound to help patients who suffer from bone fractures that do not heal through traditional methods. It offers a diverse portfolio of products to support physicians in relieving pain and addressing musculoskeletal challenges across indications and clinical areas, including knee, hand and upper extremities, foot and ankle, podiatry, trauma, general surgery, spine and neurosurgery.
- Revenue in USD (TTM)563.83m
- Net income in USD7.82m
- Incorporated2015
- Employees950.00
- LocationBioventus Inc4721 EMPEROR BOULEVARD, SUITE 100DURHAM 27703United StatesUSA
- Phone+1 (919) 474-6700
- Fax+1 (302) 655-5049
- Websitehttps://www.bioventus.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neuropace Inc | 94.86m | -23.99m | 505.49m | 209.00 | -- | 27.46 | -- | 5.33 | -0.7535 | -0.7535 | 2.98 | 0.5564 | 0.9321 | 1.46 | 7.16 | 515,565.20 | -23.57 | -35.71 | -28.36 | -44.34 | 76.77 | 73.39 | -25.28 | -60.45 | 3.94 | -3.58 | 0.7603 | -- | 22.14 | 16.67 | 17.64 | -- | -8.15 | -- |
| Mesa Laboratories Inc | 247.54m | 3.73m | 508.01m | 730.00 | 142.10 | 2.72 | 17.67 | 2.05 | 0.6471 | 0.6471 | 44.81 | 33.79 | 0.5678 | 3.40 | 6.28 | 339,097.30 | 0.8564 | -8.81 | 1.13 | -9.71 | 62.40 | 61.98 | 1.51 | -25.15 | 1.45 | 1.62 | 0.4709 | -- | 11.47 | 15.41 | 99.22 | -- | 24.60 | 0.00 |
| Orthofix Medical Inc | 818.06m | -119.12m | 529.45m | 1.62k | -- | 1.19 | -- | 0.6472 | -3.04 | -3.04 | 20.82 | 11.20 | 0.9622 | 1.37 | 6.40 | 506,224.00 | -14.01 | -10.81 | -17.28 | -13.34 | 68.27 | 70.31 | -14.56 | -11.57 | 1.38 | -1.35 | 0.2837 | -- | 7.08 | 11.69 | 16.78 | -- | 8.75 | -- |
| Anteris Technologies Global Corp | 2.14m | -84.32m | 531.03m | 136.00 | -- | 56.46 | -- | 248.25 | -2.34 | -2.34 | 0.0594 | 0.1025 | 0.1065 | 1.53 | 11.88 | 15,728.75 | -420.16 | -- | -1,527.00 | -- | 67.94 | -- | -3,945.70 | -- | 0.8032 | -- | 0.046 | -- | -1.16 | -- | -65.77 | -- | -- | -- |
| Pacific Biosciences of California Inc | 154.58m | -503.63m | 546.45m | 575.00 | -- | 15.14 | -- | 3.53 | -1.69 | -1.69 | 0.5236 | 0.1196 | 0.1372 | 1.80 | 5.15 | 268,841.80 | -44.70 | -16.31 | -47.29 | -17.71 | 30.95 | 34.48 | -325.80 | -156.40 | 5.40 | -19.94 | 0.947 | -- | -23.19 | 11.12 | -1.02 | -- | 16.89 | -- |
| Cytek Biosciences Inc | 196.83m | -12.82m | 551.10m | 692.00 | -- | 1.46 | -- | 2.80 | -0.1011 | -0.1011 | 1.54 | 2.96 | 0.3992 | 1.86 | 3.60 | 303,746.90 | -2.60 | 0.3407 | -3.02 | 0.3811 | 53.46 | 58.12 | -6.51 | 0.8678 | 4.48 | -- | 0.0213 | -- | 3.85 | 28.20 | 50.44 | -- | 30.83 | -- |
| Varex Imaging Corp | 844.60m | -70.30m | 593.16m | 2.40k | -- | 1.25 | -- | 0.7023 | -1.70 | -1.70 | 19.25 | 11.34 | 0.7267 | 1.96 | 5.37 | 351,916.70 | -6.01 | -0.3327 | -7.31 | -0.3955 | 34.39 | 33.16 | -8.28 | -0.4661 | 1.83 | 2.45 | 0.4343 | -- | 4.14 | 2.73 | -47.38 | -- | -0.5159 | -- |
| Embecta Corp | 1.08bn | 139.50m | 609.37m | 1.85k | 4.35 | -- | 3.36 | 0.5644 | 2.37 | 2.37 | 18.31 | -10.35 | 0.9757 | 2.27 | 6.35 | 583,621.60 | 12.61 | 16.69 | 16.60 | 22.65 | 63.17 | 66.74 | 12.92 | 15.71 | 1.87 | 3.18 | 1.79 | 13.07 | -3.80 | -0.1033 | 21.84 | -25.93 | -26.03 | -- |
| Tactile Systems Technology Inc | 311.51m | 18.17m | 618.03m | 1.04k | 35.62 | 3.02 | 24.82 | 1.98 | 0.7768 | 0.7768 | 13.28 | 9.18 | 1.14 | 8.38 | 8.07 | 300,398.30 | 6.64 | 1.29 | 7.72 | 1.55 | 49.87 | 49.12 | 5.83 | 1.26 | 3.20 | -- | 0.00 | 0.00 | 6.76 | 9.11 | -40.52 | 9.10 | -15.97 | -- |
| Alpha Tau Medical Ltd | 0.00 | -39.97m | 627.54m | 125.00 | -- | 8.09 | -- | -- | -0.5212 | -0.5212 | 0.00 | 0.9099 | 0.00 | -- | -- | 0.00 | -40.90 | -34.28 | -44.43 | -36.47 | -- | -- | -- | -- | -- | -- | 0.0735 | -- | -- | -- | -8.89 | -- | 11.60 | -- |
| Beta Bionics Inc | 88.57m | -77.84m | 650.68m | 404.00 | -- | 2.21 | -- | 7.35 | -2.07 | -2.07 | 2.21 | 6.70 | 0.4149 | 2.54 | 8.16 | 304,364.30 | -36.46 | -- | -40.57 | -- | 54.51 | -- | -87.89 | -- | 9.83 | -- | 0.00 | -- | 442.93 | -- | -24.17 | -- | -- | -- |
| Bioventus Inc | 563.83m | 7.82m | 667.90m | 950.00 | 71.84 | 4.02 | 11.64 | 1.18 | 0.1123 | 0.1123 | 8.39 | 2.01 | 0.7666 | 1.95 | 4.47 | 606,267.80 | 1.31 | -6.29 | 1.89 | -8.49 | 67.76 | 67.40 | 1.71 | -12.07 | 1.14 | 1.73 | 0.616 | -- | 11.89 | 11.00 | 65.33 | -- | -15.55 | -- |
| SI-Bone Inc | 193.58m | -21.76m | 668.23m | 349.00 | -- | 3.87 | -- | 3.45 | -0.5113 | -0.5113 | 4.55 | 3.98 | 0.8393 | 1.29 | 7.53 | 554,664.80 | -9.43 | -24.17 | -10.61 | -26.87 | 79.62 | 82.72 | -11.24 | -40.93 | 6.62 | -- | 0.1711 | -- | 20.37 | 19.96 | 28.67 | -- | 33.83 | -- |
| Avanos Medical Inc | 699.90m | -468.60m | 683.29m | 2.23k | -- | 0.8782 | -- | 0.9763 | -10.18 | -10.18 | 15.09 | 16.76 | 0.5139 | 2.14 | 5.76 | 314,279.30 | -34.41 | -4.82 | -39.66 | -5.42 | 52.28 | 54.01 | -66.95 | -11.32 | 1.36 | 8.92 | 0.1167 | -- | 2.15 | -0.2826 | -3,802.02 | -- | -18.86 | -- |
| CeriBell Inc | 82.81m | -52.46m | 771.22m | 281.00 | -- | 4.69 | -- | 9.31 | -1.45 | -1.45 | 2.29 | 4.43 | 0.6717 | 1.54 | 6.36 | 294,708.20 | -42.55 | -- | -48.06 | -- | 87.99 | -- | -63.35 | -- | 12.25 | -29.42 | 0.1074 | -- | 44.71 | -- | -37.30 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Bioventus Inc's reporting currency: US Dollar USD
36.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Juniper Investment Co. LLCas of 30 Sep 2025 | 6.94m | 10.36% |
| Nantahala Capital Management LLCas of 30 Sep 2025 | 5.81m | 8.68% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 2.81m | 4.20% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 2.58m | 3.85% |
| Royce & Associates LPas of 30 Sep 2025 | 1.26m | 1.89% |
| Geode Capital Management LLCas of 30 Sep 2025 | 1.10m | 1.64% |
| American Century Investment Management, Inc.as of 30 Sep 2025 | 1.09m | 1.63% |
| Kent Lake PR LLCas of 30 Sep 2025 | 1.00m | 1.49% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 876.43k | 1.31% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 811.20k | 1.21% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
